Novartis
The collaboration addresses delays in diagnosis and treatment by leveraging AI to help ensure patients with prostate and breast cancer are identified and treated more promptly.
The Copenhagen-based digital health company will work with Novartis to build digital health tools for chronic conditions where they see unmet needs and the potential for disease progression.
The partnership will focus on software that uses ECGs to find left ventricular dysfunction and atherosclerotic cardiovascular disease.
Digital care applications are among the most wanted innovations in the Germany.
The effort will be focused on using nocturnal scratch as an endpoint for atopic dermatitis.
Roundup: PainChek technology for Scotland's veterans, Novartis announces companies selected for Hea…
Also, applications are no open for NHSX Digital Health Partnership Award.
The proceeds will be used to fund the clinical development of MyopiaX, the company's lead product in childhood myopia.
New partners include companies across life sciences, insurance, health systems and global development.
The partnership will use Ada Health's AI-based platform to speed up the diagnosis of rare conditions.
The companies will be looking at the real-world data from treatment with BRAF and MEK inhibitors.